Buy Rating Affirmed for Altimmune as Pemvidutide Poised to Lead NASH Treatment Market

TipRanks17minutes ago · Ratings

Altimmune | 10-Q: Quarterly report

SEC announcement16:10 ET · Announcements

Express News | Altimmune Shares Are Trading Higher. The Company Reported Q2 Financial Results

BenzingaAug 8 11:12 ET

Express News | CORRECTION: Altimmune Q2 2024 GAAP EPS $(0.35) Misses $(0.34) Estimate, Sales $5.000K Down From $6.000K YoY

BenzingaAug 8 07:23 ET

Earnings Flash (ALT) ALTIMMUNE Reports Q2 Revenue $5,000

MT NewswiresAug 8 07:10 ET

Earnings Flash (ALT) ALTIMMUNE Reports Q2 Loss $-0.35 Per Share, Vs. Street Est of Loss $-0.35 Per Share

MT NewswiresAug 8 07:09 ET